Delivery of high-quality biomarker assays

Article type: Research Article

Authors: Swanson, Brian N.

Affiliations: Clinical Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08690, USA

Note: [] Address for correspondence: Dr. Brian N. Swanson, Director, Clinical Laboratory, Bristol-Myers Squibb Company, 3 Hamilton Health Place, Hamilton, NJ 08690, USA. Tel.: +1 609 689 4567; Fax: +1 609 689 4250; E-mail: brian.swanson@bms.com

Abstract: Biomarker measurements now support key decisions throughout the drug development process, from lead optimization to regulatory approvals. They are essential for documenting exposure-response relationships, specificity and potency toward the molecular target, untoward effects, and therapeutic applications. In a broader sense, biomarkers constitute the basis of clinical pathology and laboratory medicine. The utility of biomarkers is limited by their specificity and sensitivity toward the drug or disease process and by their overall variability. Understanding and controlling sources of variability is not only imperative for delivering high-quality assay results, but ultimately for controlling the size and expense of research studies. Variability in biomarker measurements is affected by: biological and environmental factors (e.g., gender, age, posture, diet and biorhythms), sample collection factors (e.g., preservatives, transport and storage conditions, and collection technique), and analytical factors (e.g., purity of reference material, pipetting precision, and antibody specificity). The quality standards for biomarker assays used in support of nonclinical safety studies fall under GLP (FDA) regulations, whereas, those assays used to support human diagnostics and healthcare are established by CLIA (CMS) regulations and accrediting organizations such as the College of American Pathologists. While most research applications of biomarkers are not regulated, biomarker laboratories in all settings are adopting similar laboratory practices in order to deliver high-quality data. Because of the escalation in demand for biomarker measurements, the highly-parallel (multi-plexed) assay platforms that have fueled the rise of genomics will likely evolve into the analytical engines that drive the biomarker laboratories of tomorrow.

Keywords: assay, bioanalytical, biomarker, CLIA, drug development, GLP, pharmaceutical, quality, regulations, review, validation

Journal: Disease Markers, vol. 18, no. 2, pp. 47-56, 2002